Published in J Clin Psychiatry on February 01, 2005
Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bull (2009) 1.95
Differences in mortality and suicidal behaviour between treated and never-treated people with schizophrenia in rural China. Br J Psychiatry (2009) 1.55
Premature death in adults with 22q11.2 deletion syndrome. J Med Genet (2009) 1.42
Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care (2009) 1.30
Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol (2012) 1.25
Are there modifiable risk factors which will reduce the excess mortality in schizophrenia? J Psychopharmacol (2010) 1.24
The catatonic dilemma expanded. Ann Gen Psychiatry (2006) 1.18
Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions. Eur Arch Psychiatry Clin Neurosci (2013) 1.07
The impact of obesity on health care costs among persons with schizophrenia. Gen Hosp Psychiatry (2008) 1.02
Toxoplasma gondii in individuals with schizophrenia: association with clinical and demographic factors and with mortality. Schizophr Bull (2007) 1.00
A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case. BMC Syst Biol (2015) 0.99
Poor clinical outcomes among pneumonia patients with schizophrenia. Schizophr Bull (2010) 0.98
Inequalities in lung cancer care of elderly patients with schizophrenia: an observational cohort study. Psychosom Med (2014) 0.92
Clozapine-induced mitochondria alterations and inflammation in brain and insulin-responsive cells. PLoS One (2013) 0.92
Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin Neurosci (2009) 0.92
Anthropometric parameters as indicators of metabolic derangements in schizophrenia patients stabilized on olanzapine in an Indian rural population. J Neurosci Rural Pract (2012) 0.92
Mortality in schizophrenia: clinical and serological predictors. Schizophr Bull (2013) 0.91
A Review of Brain-derived Neurotrophic Factor as a Candidate Biomarker in Schizophrenia. Clin Psychopharmacol Neurosci (2012) 0.90
Incident somatic comorbidity after psychosis: results from a retrospective cohort study based on Flemish general practice data. BMC Fam Pract (2011) 0.89
Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand (2012) 0.89
Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. BMC Psychiatry (2008) 0.87
Medical comorbidity in patients with schizophrenia and alcohol dependence. Schizophr Res (2008) 0.87
An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia. J Dual Diagn (2013) 0.87
A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia. Acta Psychiatr Scand (2009) 0.87
Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms. Schizophr Bull (2009) 0.86
Efficacy of lifestyle interventions in physical health management of patients with severe mental illness. Ann Gen Psychiatry (2011) 0.84
Treatment of tobacco use disorders in smokers with serious mental illness: toward clinical best practices. Harv Rev Psychiatry (2015) 0.83
Progression from selective to general involvement of hippocampal subfields in schizophrenia. Mol Psychiatry (2016) 0.83
Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia. Int Clin Psychopharmacol (2015) 0.83
Differentiating nicotine- versus schizophrenia-associated decreases of the alpha7 nicotinic acetylcholine receptor transcript, CHRFAM7A, in peripheral blood lymphocytes. J Neural Transm (Vienna) (2008) 0.82
Are women with psychosis receiving adequate cervical cancer screening? Can Fam Physician (2010) 0.82
Childhood onset schizophrenia and early onset schizophrenia spectrum disorders. Child Adolesc Psychiatr Clin N Am (2013) 0.82
Lost in the rush to national reform: recommendations to improve impact on behavioral health providers in rural areas. J Health Care Poor Underserved (2012) 0.81
Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia. Psychopharmacology (Berl) (2013) 0.80
The use of psychiatric drugs and worsening body mass index among inpatients with schizophrenia. Int Clin Psychopharmacol (2014) 0.80
Reliability and practicality of measuring waist circumference to monitor cardiovascular risk among community mental health center patients. Community Ment Health J (2013) 0.80
European network for promoting the physical health of residents in psychiatric and social care facilities (HELPS): background, aims and methods. BMC Public Health (2009) 0.79
Characterization of schizophrenia adverse drug interactions through a network approach and drug classification. Biomed Res Int (2013) 0.79
Adherence to common cardiovascular medications in patients with schizophrenia vs. patients without psychiatric illness. Gen Hosp Psychiatry (2015) 0.79
Smoking status as a potential confound in the BOLD response of patients with schizophrenia. Schizophr Res (2008) 0.78
Prevalence of night eating in obese individuals with schizophrenia and schizoaffective disorder. Compr Psychiatry (2012) 0.78
Accuracy of self-reported medical problems in patients with alcohol dependence and co-occurring schizophrenia or schizoaffective disorder. Schizophr Res (2011) 0.78
The effectiveness of lifestyle interventions to reduce cardiovascular risk in patients with severe mental disorders: meta-analysis of intervention studies. Community Ment Health J (2013) 0.78
Making the journey with me: a qualitative study of experiences of a bespoke mental health smoking cessation intervention for service users with serious mental illness. BMC Psychiatry (2016) 0.77
Mortality among long-stay patients with schizophrenia during the setting-up of community facilities under the Yuli model. Health Psychol Behav Med (2014) 0.76
Illicit drug use in heavy smokers with and without schizophrenia. Schizophr Res (2012) 0.76
High Prevalence of Obesity, Hypertension, Hyperlipidemia, and Diabetes Mellitus in Japanese Outpatients with Schizophrenia: A Nationwide Survey. PLoS One (2016) 0.75
Effectiveness of a multi-component Smoking Cessation Support Programme (McSCSP) for patients with severe mental disorders: study design. Int J Environ Res Public Health (2013) 0.75
Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder. J Psychiatr Pract (2016) 0.75
Mortality among patients with schizophrenia and vocational rehabilitation program services under Taiwan's psychiatric care reform. Int J Ment Health Syst (2016) 0.75
Preliminary Examination of Olanzapine and Diet Interactions On Metabolism in a Female Macaque. J Endocrinol Diabetes (2015) 0.75
Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study. Neuropsychiatr Dis Treat (2017) 0.75
Serious mental illness and medical comorbidities: Findings from an integrated health care system. J Psychosom Res (2017) 0.75
Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. Int Clin Psychopharmacol (2017) 0.75
Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations. CNS Drugs (2017) 0.75
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA (2007) 9.68
Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA (2005) 6.89
Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension (2006) 5.59
Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation (2005) 3.85
2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 3.63
2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 3.35
Sodium, blood pressure, and cardiovascular disease: further evidence supporting the American Heart Association sodium reduction recommendations. Circulation (2012) 3.14
Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications. Circulation (2006) 3.10
The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: a call to action from the American Heart Association. Circulation (2011) 2.89
Individual blood pressure responses to changes in salt intake: results from the DASH-Sodium trial. Hypertension (2003) 2.87
Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol (2005) 2.62
Apolipoprotein-mediated pathways of lipid antigen presentation. Nature (2005) 2.61
Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence. Biol Psychiatry (2010) 2.45
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry (2005) 2.35
Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation (2004) 2.33
Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry (2006) 2.31
Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol (2008) 2.21
Psychosocial factors in outcomes of heart surgery: the impact of religious involvement and depressive symptoms. Health Psychol (2004) 2.17
Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation (2005) 2.13
Marital status, dipping and nocturnal blood pressure: results from the Dietary Approaches to Stop Hypertension trial. J Hypertens (2014) 2.09
Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation (2006) 2.07
A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol (2005) 2.07
Circulating long-chain ω-3 fatty acids and incidence of congestive heart failure in older adults: the cardiovascular health study: a cohort study. Ann Intern Med (2011) 2.06
Retracted Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation (2008) 2.04
Effects of 4 weight-loss diets differing in fat, protein, and carbohydrate on fat mass, lean mass, visceral adipose tissue, and hepatic fat: results from the POUNDS LOST trial. Am J Clin Nutr (2012) 1.96
Retracted Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation. Circ Res (2008) 1.85
The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom (2003) 1.83
Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol (2003) 1.70
Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. Arch Intern Med (2004) 1.69
Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation (2006) 1.69
Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation (2010) 1.67
The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology (2007) 1.67
A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol (2007) 1.66
Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation (2006) 1.66
Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry (2004) 1.65
Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness. Psychopharmacology (Berl) (2007) 1.64
Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry (2005) 1.61
Association of plasma phospholipid long-chain ω-3 fatty acids with incident atrial fibrillation in older adults: the cardiovascular health study. Circulation (2012) 1.54
Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control. J Clin Hypertens (Greenwich) (2004) 1.53
Adherence is a multi-dimensional construct in the POUNDS LOST trial. J Behav Med (2009) 1.53
Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation (2002) 1.51
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol (2009) 1.49
Reassessing the safety of varenicline. Am J Psychiatry (2013) 1.48
Smoking behavior and interest in quitting among homeless smokers. Addict Behav (2004) 1.48
LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol (2003) 1.46
Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia. Hum Psychopharmacol (2009) 1.44
Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. J Lipid Res (2007) 1.44
Plasma phospholipid long-chain ω-3 fatty acids and total and cause-specific mortality in older adults: a cohort study. Ann Intern Med (2013) 1.43
Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population. Am J Med (2012) 1.42
A further subgroup analysis of the effects of the DASH diet and three dietary sodium levels on blood pressure: results of the DASH-Sodium Trial. Am J Cardiol (2004) 1.41
Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry (2004) 1.41
Training in a clozapine clinic for psychiatry residents: a plea and suggestions for implementation. Acad Psychiatry (2013) 1.40
Low-density lipoprotein lowering therapy: an analysis of the options. J Am Coll Cardiol (2002) 1.40
Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med (2003) 1.39
Treatment noncompliance with orally disintegrating olanzapine tablets. Can J Psychiatry (2003) 1.39
A single dose of nicotine enhances reward responsiveness in nonsmokers: implications for development of dependence. Biol Psychiatry (2007) 1.39
Sodium and blood pressure: no data dredging, please! Am J Hypertens (2003) 1.39
Beyond capacity: identifying ethical dilemmas underlying capacity evaluation requests. Psychosomatics (2012) 1.39
The role of triglycerides in atherosclerosis. Curr Cardiol Rep (2011) 1.38
Weight gain and 10-year cardiovascular risk with sustained tobacco abstinence in smokers with serious mental illness: a subgroup analysis of a randomized trial. J Clin Psychiatry (2016) 1.38
Insulin receptor substrate 1 gene variation modifies insulin resistance response to weight-loss diets in a 2-year randomized trial: the Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST) trial. Circulation (2011) 1.37
Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry (2010) 1.33
Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol (2003) 1.32
A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol (2003) 1.29
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res (2008) 1.27
Cortical thickness abnormalities in cocaine addiction--a reflection of both drug use and a pre-existing disposition to drug abuse? Neuron (2008) 1.27
Single dose of a dopamine agonist impairs reinforcement learning in humans: evidence from event-related potentials and computational modeling of striatal-cortical function. Hum Brain Mapp (2009) 1.25
Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation. Arterioscler Thromb Vasc Biol (2006) 1.24
Alternatives for macronutrient intake and chronic disease: a comparison of the OmniHeart diets with popular diets and with dietary recommendations. Am J Clin Nutr (2008) 1.23
Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins. Arterioscler Thromb Vasc Biol (2009) 1.23
Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry (2004) 1.22
Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol (2010) 1.22
Combination lipid therapy in type 2 diabetes. N Engl J Med (2010) 1.20
Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation (2011) 1.19
Neural substrates of attentional bias for smoking-related cues: an FMRI study. Neuropsychopharmacology (2010) 1.17
FTO genotype and 2-year change in body composition and fat distribution in response to weight-loss diets: the POUNDS LOST Trial. Diabetes (2012) 1.16
Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease. J Am Heart Assoc (2012) 1.15
Effect of dietary sodium intake on blood lipids: results from the DASH-sodium trial. Hypertension (2004) 1.14
Association between CHRNA5 genetic variation at rs16969968 and brain reactivity to smoking images in nicotine dependent women. Drug Alcohol Depend (2011) 1.14
Dietary intake profile of patients with schizophrenia. Ann Clin Psychiatry (2006) 1.14